Key Pfizer-Sponsored Data Presentations at the American Society of - PDF document

Key Pfizer-Sponsored Data Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting 2019 The embargo on most data will lift on Wednesday, May 15 at 5:00 PM ET unless otherwise noted. Avelumab: (Abstract 101) Biomarker Analyses from JAVELIN Renal 101: Avelumab + Axitinib (A + Ax) vs Sunitinib (S) in Advanced Renal Cell Carcinoma (aRCC). Choueiri TK. Saturday, June 1. Session Type: Clinical Science Symposium. Presentation Time: 8:12 a.m. – 8:24 a.m. CDT. Location: Hall D1. (Abstract 4072) First-Line Avelumab + Axitinib in Patients (Pts) with Advanced Hepatocellular Carcinoma (HCC): Results from a Phase 1b Trial (VEGF Liver 100). Kudo M. Monday, June 3. Session Type: Poster. Presentation Time: 8:00 a.m. – 11:00 a.m. CDT. Location: Hall A. (Abstract 9569) Integrative Molecular Analysis of Metastatic Merkel Cell Carcinoma to Identify Predictive Biomarkers of Response to Avelumab. Georges S. Monday, June 3. Session Type: Poster. Presentation Time: 1:15 p.m. – 4:15 p.m. CDT. Location: Hall A. (Abstract TPS2660) JAVELIN BRCA/ATM: A Phase 2 Trial of Avelumab (anti–PD-L1) Plus Talazoparib (PARP Inhibitor) in Patients with Advanced Solid Tumors with a BRCA 1/2 Or ATM defect. Hyman D. Saturday, June 1. Session Type: Poster. Presentation Time: 8:00 a.m. – 11:00 a.m. CDT. Location: Hall A. (Abstract 4552) 5-Factor Prognostic Model for Survival of Patients with Metastatic Urothelial Carcinoma Receiving 3 Different Post-Platinum PD-L1 Inhibitors. Sonpavde GP. Monday, June 3. Session Type: Poster. Presentation Time: 1:15 p.m. – 4:15 p.m. Location: Hall A. (Abstract TPS3169) Phase 1, Open-Label, Dose-Escalation Study of M3814 + Avelumab ± Radiotherapy [RT] in Patients (Pts) with Advanced Solid Tumors. Bendell J. Saturday, June 1. Session Type: Poster. Presentation Time: 8:00 a.m. – 11:00 a.m. CDT. Location: Hall A. Axitinib: (Abstract 4573) Adjuvant Axitinib Dose Modification in Renal Cell Carcinoma (RCC): Analysis of the ATLAS study. Quinn DI . Monday, June 3. Session Type: Poster. Presentation Time: 1:15 p.m. – 4:15 p.m. CDT. Location: Hall A. Bosutinib: (Abstract 7012) Primary Results of the Phase 4 BYOND Study of Bosutinib (BOS) for Pretreated Chronic Phase (CP) Chronic Myeloid Leukemia (CML). Gambacorti-Passerini C. Monday, June 3. Session Type: Poster Discussion. Presentation Time: 4:30 p.m. – 6:00 p.m. CDT. Location: E450. (Abstract 7051) Cardiac, Vascular, and Hypertension Safety of Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia in the BFORE trial. Cortes JE. Monday, June 3. Session Type: Poster. Presentation Time: 8:00 a.m. – 11:00 a.m. CDT. Location: Hall A. 1

Enzalutamide: (Abstract 5036) Interlesional Response Assessment with 18F-Sodium Fluoride (18F-NaF) PET/CT in Men with Chemotherapy-Naive Bone Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide (ENZA). Kyriakopoulos C. Saturday, June 1. Session Type: Poster. Presentation Time: 1:15 p.m. – 4:15 p.m. CDT. Location: Hall A. (Abstract 5044) Health-Related Quality Of Life (HRQoL) and Pain Progression with Enzalutamide (ENZ) in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) from the ARCHES Study. Stenzl A. Saturday, June 1. Session Type: Poster. Presentation Time: 1:15 p.m. – 4:15 p.m. PM CDT. Location: Hall A. (Abstract 5048) ARCHES: Efficacy of Androgen Deprivation Therapy (ADT) with Enzalutamide (ENZA) or Placebo (PBO) in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). Armstrong A. Saturday, June 1. Session Type: Poster. Presentation Time: 1:15 p.m. – 4:15 p.m. CDT. Location: Hall A. Glasdegib: (Abstract 7010) Low-Dose Cytarabine with or without Glasdegib in Newly Diagnosed Patients with Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial. Smith BD. Monday, June 3. Session Type: Poster Discussion. Presentation Time: 4:30 p.m. – 6:00 p.m. Location E450. Inotuzumab Ozogamicin: (Abstract 7025) Time from Randomization to First Subsequent Induction/Salvage Therapy (ST) in Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (InO) in the Phase 3 INO-VATE Trial. Jabbour E. Monday, June 3. Session Type: Poster. Presentation Time: 8:00 a.m. – 11:00 a.m. CDT. Location: Hall A. (Abstract 7029) Inotuzumab Ozogamicin (InO) Treatment in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL): Outcomes of Patients Treated in Salvage One with a Long Duration of First Remission. Kantarjian H. Monday, June 3. Session Type: Poster. Presentation Time: 8:00 a.m. – 11:00 a.m. CDT. Location: Hall A. Lorlatinib: (Abstract 9019) Early Circulating Tumor (ct)DNA Dynamics and Efficacy of Lorlatinib in Patients (Pts) with Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC). Shaw AT. Sunday, June 2. Session Type: Poster Discussion. Presentation Time: 8:00 a.m. – 11:00 a.m. CDT. Location: Hall D1. Palbociclib: (Abstract 6013) Palbociclib Plus Cetuximab Versus Placebo Plus Cetuximab in Platinum-Resistant, Cetuximab- Naive, HPV-Unrelated Head and Neck Cancer: A Double-Blind Randomized Phase II Trial (PALATINUS). Adkins D. Saturday, June 1. Session Type: Poster Discussion. Presentation Time: 1:15 p.m. – 4:15 p.m. CDT. Location: S100a. 2

(Abstract 1055) Real-World Evidence of Male Breast Cancer (BC) Patients Treated with Palbociclib (PAL) in Combination with Endocrine Therapy (ET). Huang Bartlett C. Sunday, June 2. Session Type: Poster. Presentation Time: 8:00 a.m. – 11:00 a.m. CDT. Location: Hall A. (Abstract 1060) Association of Drug-Related Polymorphisms with Palbociclib-Related Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3 (P2/3). Hiroji I. Sunday, June 2. Session Type: Poster. Presentation Time: 8:00 a.m. – 11:00 a.m. CDT. Location: Hall A. Talazoparib: (Abstract 5076) Clinical and Safety Outcomes of TALAPRO-2: A Two-Part Phase III Study of Talazoparib (TALA) in Combination with Enzalutamide (ENZA) in Metastatic Castration-Resistant Prostate Cancer (mCRPC). Agarwal N. Saturday, June 1. Session Type: Poster. Presentation Time: 1:15 p.m. – 4:15 p.m. CDT. Location: Hall A. (Abstract 1044) Efficacy and Safety of Talazoparib (TALA) or Physician's Choice of Therapy (PCT) in United States Patients (Pts) with HER2- Germline BRCA1/2 -Mutated (gBRCAm) Locally Advanced/Metastatic Breast Cancer (LA/MBC) in the EMBRACA Study. Diab S. Sunday, June 2. Session Type: Poster. Presentation Time: 8:00 a.m. – 11:00 a.m. CDT. Location: Hall A. (Abstract 1071) Outcomes of Talazoparib (TALA) Versus Physician's Choice of Chemotherapy (PCT) in Patients (Pts) with Advanced Breast Cancer (ABC) and a Germline BRCA (gBRCA) Mutation by Line of Chemotherapy (CT) in the EMBRACA Trial. Ettl J. Sunday, June 2. Session Type: Poster. Presentation Time: 8:00 a.m. – 11:00 a.m. CDT. Location: Hall A. (Abstract TPS5092) TALAPRO-2: Part 2 (P2) of the Placebo-Controlled Phase 3 Study of Talazoparib (TALA) with Enzalutamide (ENZA) in Metastatic Castration-Resistant Prostate Cancer (mCRPC). Agarwal N. Saturday, June 1. Session Type: Poster. Presentation Time: 1:15 p.m. – 4:15 p.m. CDT. Location: Hall A. Early-Pipeline Assets: (Abstract 3064) Rethinking About the Dose Limiting Toxicities (DLTs): They Can Be Equivocal!. Zhong W. Saturday, June 1. Session Type: Poster. Presentation Time: 8:00 a.m. – 11:00 a.m. CDT. Location: Hall A. ### 3